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Introduction: Lung cancer is the leading global cause of cancer-
related mortality. Interindividual variability in treatment response
and cancer outcomes has focused attention on genetic polymor-
phisms as prognostic markers. We evaluated the overall contribution
of candidate polymorphism association studies to our current under-
standing of the genetic predictors of lung cancer outcomes.
Methods: We examined the results of 90 studies that evaluated
associations between genetic polymorphisms and lung cancer out-
comes published between January 1990 and May 2009.
Results: A total of 170 genetic variations in 90 studies were
identified. Overall survival was a primary outcome in 81% of the
studies and toxicity in 19%. Candidate polymorphisms in the DNA
repair/synthesis pathway were the most frequently studied. Strong
evidence in large-scale confirmatory studies of any single polymor-
phism was lacking. Polymorphisms of EGFR, XRCC1, and ERCC1
were associated with pharmacogenetic outcomes, whereas polymor-
phisms of MDM2, p53, and GSTM1 were associated with prognostic
outcomes. All remaining polymorphisms had results lacking or
failing replication testing. Heterogeneity in study populations, incom-
plete reporting of important population or study characteristics, inade-
quate power, and inconsistencies in methodology were common.
Conclusions: Although the quality of existing studies involving the
candidate polymorphism approach is highly variable, a small set of
candidate polymorphisms was identified as potential biomarkers of
clinical or pharmacogenetic outcome and would benefit from further
replication testing. Newer approaches including haplotype tagging,
pathway, genome-wide association, and combination methods with
validative approaches may facilitate a more accurate prediction of
lung cancer outcomes by genetic variation.
Key Words: Lung cancer, Single-nucleotide polymorphisms, Out-
comes, Prognosis.
(J Thorac Oncol. 2011;6: 296–304)
An estimated 1.5 million incident lung cancers occurworldwide each year, accounting for 12% of all cancers.
It remains the leading global cause of cancer-related mortality
with 5-year survival rates of 10 to 15%. In non-small cell
lung cancer (NSCLC), almost half of the patients present with
advanced disease, where chemotherapy provides modest sur-
vival benefits. Treatment with a platinum-based chemother-
apy is standard for locally advanced or advanced disease
either in the adjuvant or metastatic setting. There are benefits
for second-line chemotherapy and additional roles for bio-
logic agents such as epidermal growth factor receptor ty-
rosine kinase inhibitors (EGFR-TKIs).
Despite progress in cancer drug development, there
remains considerable interindividual variability in drug re-
sponse, toxicity, and cancer outcomes, which cannot be
explained by clinical and tumor molecular factors alone.
Thus, inherited genetic determinants may complement tradi-
tional clinical factors (such as performance status, tumor size,
stage of disease, and response to chemotherapy) and allow a
more accurate approach to outcome prediction.
Inherited genetic variations such as single-nucleotide
polymorphisms (SNPs) have been studied in lung cancer risk
for several decades, focusing on xenobiotic metabolism
genes, especially those involved in tobacco carcinogen me-
tabolism. In contrast, the evaluation of genetic polymor-
phisms in lung cancer outcome or pharmacogenetics is a
recently maturing field. We reviewed the published literature
on the relationship between genetic polymorphisms and lung
cancer outcomes (survival, therapy, response, or toxicity) or
prognosis to gain insights into achievements in this field and
to highlight the direction of future research.
MATERIALS AND METHODS
Search Strategy
Literature searches of PubMed (1990 to May 2009),
EMBASE (1990 to May 2009), AACR Annual Meeting
2008, and ASCO Annual Meeting 2007–2008 were per-
formed using keywords and MeSH terms. MeSH terms in-
cluded “polymorphisms, single nucleotide,” “lung neo-
plasms,” “outcome assessment (healthcare),” “outcome and
process assessment (healthcare),” “survival,” “radiotherapy,”
“chemotherapy,” and “drug therapy.” Keywords included
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“polymorphism,” “single nucleotide polymorphism,” “lung
cancer,” “outcome,” “survival,” “prognosis,” “toxicity,”
“pharmacogenetics,” “response,” “efficacy,” “radiotherapy,”
and “chemotherapy.” Searches were limited to human studies
and English language. Citation lists of retrieved articles were
checked to ensure sensitivity of the search strategy.
Study Selection
Duplicate and obviously unrelated articles were elimi-
nated by a single reviewer (B.Y.). Abstracts of the remaining
articles were examined independently by three reviewers
(B.Y., G.L., and A.H.) to determine whether the full-text
article should be obtained. Articles published in English-
language, peer-reviewed journals that assessed the relation-
ship between germline polymorphic variants and major out-
comes of interest were included. As in our parallel review,1
we excluded single case reports, studies that presented ag-
gregate data for several cancers but not of lung cancer alone,
and opinion pieces, such as editorials and letters to the editor.
Lung cancer studies were defined as those that evaluated
small cell and/or non-small cell carcinomas in the tissues of
the lung. Articles that considered any of the following major
outcomes were reviewed: overall survival (OS), disease-free
survival (DFS), cancer-specific survival (CSS), progression-
free survival (PFS), time to progression (TTP), response rate
(RR), and toxicity (acute or chronic). Given the variable
outcomes studied and the methodological inconsistencies
between studies, a descriptive review as opposed to a meta-
analysis was undertaken.
RESULTS
Our literature search identified 90 studies that analyzed
the association between genetic polymorphisms and lung
cancer outcomes. Most included more than one polymor-
phism, either alone or in combination, with a total of 170
different genetic variations analyzed. All were case series or
cohort observational studies or subsets of cohort, case-con-
trol, or randomized controlled studies. Study size ranged from
36 to 731 patients, with a median of 144 (mean n  202).
Study populations, reported or inferred, were predominantly
Caucasian or Asian (46 and 39 studies, respectively). Overall
survival (OS) was the primary outcome measure in 73 (81%)
of the studies, while toxicity was an outcome in only 17
studies (19%). Adequate reporting of treatment data (name
and dose of drug/regimen and radiation type/dose) was absent
in 32% of the studies. Other outcome measures included RR,
PFS, and DFS, 1-year survival, and 3-year survival. While the
majority of studies (n  64) involved NSCLCs alone, 2
considered only small cell lung cancers (SCLC), 20 included
all histologies, and 4 included adenocarcinomas alone. Poly-
morphisms in the DNA repair/synthesis pathway were the
most frequently studied (28 studies). Fifty-two percent of the
studies were published in the last 3 years (2007–2009).
Practically, all studies were acknowledged to be exploratory
or in need of validation or replication. Supplementary Table
1A presents those polymorphisms or pathways that have been
most frequently studied (see Tables, Supplemental Digital
Content 1, http://links.lww.com/JTO/A42, which demon-
strates all polymorphisms or pathways studied). We present
all others that have been investigated in more than one study
(Supplementary Table 2A, http://links.lww.com/JTO/A42) and
those that have only been analyzed in single/unreplicated studies
(Supplementary Table 3A, http://links.lww.com/JTO/A42). We
describe the association with outcome separately for polymor-
phisms in patients treated or not treated with specific drugs,
where pharmacogenetic evaluations are meaningful.
DNA Synthesis/Repair Pathway Polymorphisms
and Platinum Therapy
Platinum compounds form cytotoxic DNA adducts that
result in distortion of DNA, destabilization of the double
helix, and inhibition of DNA replication. Circulating plati-
num-DNA adduct levels correlate with clinical outcome.2
Impaired DNA repair mechanisms result in decreased
removal of platinum-DNA adducts and may improve clin-
ical response and cancer survival.2,3 Polymorphisms in
DNA repair genes may consequently contribute to interin-
dividual diversity in DNA repair capacity. Four major
DNA repair mechanisms have been studied for genetic
variation with clinical parameters: mismatch repair, base
excision repair, nucleotide excision repair, and double-
strand break repair.
The x-ray repair cross-complementing group 1
(XRCC1) gene belongs to the DNA base excision repair
pathway. Ten studies have investigated XRCC1 Arg399Gln
and its association with outcomes or toxicities in lung cancer
(Figure 1; Supplementary Table 1A).4–13 Four studies of
platinum-treated patients found a positive effect of the Gln
allele on survival/response outcomes.4–7 A further study
where treatment was not specified (40% of the population had
stage III or IV disease and therefore likely did receive
platinum chemotherapy) also confirmed a significant favor-
able association with the Gln/Gln genotype.8 The one study
with opposite results mainly used carboplatin (71%) as op-
posed to cisplatin as the platinum agent.9 In contradistinction,
two studies involving patients who were not treated with
platinum therapy described no significant association with
survival.10,11 A third (n  46) showed a worse survival
outcome with Gln/Gln; however, there were only three pa-
tients with this genotype.4 Toxicity associations with XRCC1
Arg399Gln12,13 and outcome associations with the XRCC1
Arg194Trp polymorphism have revealed conflicting re-
sults.7,10,11,13 These findings are inconclusive but suggestive
of XRCC1 Arg399Gln as a potential predictive marker of
cisplatin response and outcome. The biologic effect of the
XRCC1 protein on cisplatin drug action is indirect and may be
through suboptimal DNA repair mechanism conferred by the
at-risk genotype.
Excision repair cross-complementation group 1
(ERCC1) and ERCC2/XPD are two major proteins of the
nucleotide excision repair family and are responsible for
platinum-DNA adduct removal.14 High levels of ERCC1
mRNA are associated with resistance to platinum-based che-
motherapy in multiple cancers.15–19 In three of four Asian
studies, the T allele of ERCC1 codon 118 C/T was associated
with worse outcomes in patients treated with platinum-based
chemotherapy (Figure 1; Supplementary Table 1A). The
variant alleles (T/T  C/T) were associated with worse OS
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FIGURE 1. Summary of NSCLC outcome studies. a, No confidence intervals reported. b, Descriptive data only, no statistical
data provided. c, Univariate data. d, Data differs from published - provided by author on request. S/C/R, surgery  chemo-
therapy  radiotherapy; NS, not specified; LOR, lack of response; OS, overall survival; HR, hazard ratio; Tox, toxicity; PFS, pro-
gression-free survival; TTP, time to progression.
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compared with C/C in two of these studies.20,21 The third
study assessed only response; those harboring one or two
variant alleles were less likely to respond to chemotherapy
than C/C.22 In the absence of platinum therapy, no significant
association was found.23 In contrast, four Caucasian-based
studies involving platinum therapy (n  65–214) reported no
significant association with survival or toxicity out-
comes.6,24–26 A further study reported a lower response to
platinum-based chemotherapy with T/T, but there was no
association with toxicity or survival on multivariate analysis.5
Thus, the T allele may be a predictive marker of poor
outcome in patients of Asian ancestry treated with cisplatin-
based regimens.
Data for other DNA repair gene (ERCC1 C8092A,
MDR1, iASPP, CDA, hMSH2, XPA) polymorphisms have
been inconsistent or are from unreplicated studies (Supple-
mentary Table 1A).
Epidermal Growth Factor Receptor and
EGFR-TKIs
Human EGFR, a transmembrane glycoprotein with an
intracellular tyrosine protein kinase domain, plays a crucial
role in cellular proliferation, differentiation, and survival.27
Although EGFR is overexpressed in 40 to 80% of NSCLC,
EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib
produce clinical responses in only a small subset of patients.28
EGFR activating mutations and EGFR amplification are as-
sociated with gefitinib29 and erlotinib response.30
EGFR Intron 1 CA Repeat
Shorter alleles of a CA dinucleotide repeat polymor-
phism in intron 1 of EGFR, of lower frequency in Asian
populations, are associated with an increase in transcription
of EGFR.31 A single Asian study identified those patients
with two longer alleles to be associated with worse survival
(log-rank p  0.04, univariate survival analysis) with no
correlation identified between EGFR somatic mutations and
EGFR intron 1 (CA)n repeats (n  18).32 Although no
association between EGFR intron 1 (CA)n polymorphism
length and OS was identified in gefitinib-treated patients in
six studies,33–38 the longer allele was associated with poorer
RR/PFS/TTP in three of these.35–37 In contrast, the longer
allele was associated with improved OS in a single US study
of patients who were not treated with gefitinib (hazard ratio
[HR] 0.66; log-rank p  0.03).38 These data suggest a
predictive effect of allele length on gefitinib therapy.
The EGFR-G216T polymorphism is located in the tran-
scriptional start site of the EGFR gene promoter region near
multiple nuclear regulatory affinity sites. Of three studies eval-
uating associations between this polymorphism and outcomes in
patients with NSCLC treated with gefitinib,33,35,39 two found
significant results. A US study reported worse PFS, but no
difference in OS, in patients carrying the -216G/G genotype
(log-rank p 0.005).35 Consistent with these data, the EGFR*1
(EGFR-216G/-191C) haplotype was associated with signifi-
cantly worse survival in a second study (HR 1.85 [95% confi-
dence interval {CI} 1.1–3.3]).33
ABCG2 is a transporter protein that influences the
absorption and disposition of various substrates including
gefitinib. In a single unvalidated study (n  173) evaluating
multiple ABC polymorphisms, the variant A allele of ABCG2
C421A was significantly associated with the occurrence of
diarrhea but not with skin toxicity.39
p53
Fifty percent of NSCLCs have dysregulated p53 tumor
suppressor gene function.40 The Pro variant of p53 Arg72Pro
is associated with reduced ability to induce apoptosis,41 lower
response rates, and worse outcomes in some cancers.42 The
association between this polymorphism and NSCLC survival
has been investigated in six studies (Figure 1).43–48 A single
study (n  170) identified a shorter OS with the Arg/Pro
genotype (AHR 2.27 [95% CI 1.1–4.7]) compared with the
homozygote wild-type.43 A second study (n  121) reported
a shorter OS with the Pro/Pro genotype (p  0.03),44
whereas in a third study (n  114), the same genotype
(Pro/Pro) was associated with a shorter survival, especially
for male patients (p  0.028) and those with squamous cell
carcinoma (p  0.013).45 Although no association with over-
all survival was seen in a fourth study (n 148), the Pro/Pro
genotype was associated with shorter PFS when compared
with Arg/- (AHR 1.95 [95% CI 1.2–3.2]).46 Two additional
studies (n  443, 619) yielded negative results.47,48 The
combined effect of the p53 codon 72 and PIN3 polymor-
phisms (p53PIN3) on prognosis was tested in a further
study.49 Worse OS was reported with the homozygous variant
for either SNP (AHR 1.43 [95% CI 1.1–1.9]. These studies
had varied patient enrollment, different comparators, and
included different treatment types and prognostic factors in
the analysis; none systematically assessed tumor p53 muta-
tion/overexpression. Other polymorphisms49 and race48 may
confound these relationships.
MDM2
MDM2 is a negative regulator of p53.50 The MDM2
gene promoter region contains a SNP (MDM2 T309G) whose
variant G allele results in increased MDM2 mRNA and
protein expression and consequent downregulation of p53
activity.51 Two studies with very distinct populations each
found an association between the G variant of this polymor-
phism and shorter OS. In stage I/II disease treated with
surgical resection, the G/G genotype was associated with
worse adjusted OS (AHR 1.57 [95% CI 1.0–2.4], p 
0.04).50 Han et al.46 included stage III/IV disease treated with
first-line chemotherapy and also reported that G/- predicted
shorter OS (HR 1.7, p  0.03). These modest-sized studies
are promising but require further replication in large studies.
Glutathione S-Transferases
Glutathione S-transferases (GSTs) are phase II meta-
bolic enzymes involved in the detoxification of both carcin-
ogens and drugs such as cisplatin by glutathione conjugation.
Ten studies assessed the association between lung cancer
outcomes and various GST (GSTM1, GSTP1, GSTT1) poly-
morphisms (Supplemental Table 1A). Three studies involved
surgery alone as treatment, whereas only four of the remain-
ing studies reported whether cisplatin was part of the treat-
ment protocol. GSTM1-null genotype was significantly asso-
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ciated with shorter survival in NSCLC patients in two of six
studies (Figure 1).52,53 Sweeney et al.52 report a relative risk
of death of 1.36 (95% CI 1.0–1.8) with GSTM1-null com-
pared with GSTM1-present in a cohort of 274 predominantly
Caucasian patients of all disease stages and histologic types.
A similar cohort (all stages, all histologies), studied by
Gonlugur et al.,53 also identified GSTM1-null as an indepen-
dent risk factor for shorter survival (p  0.001). Study size,
histology, disease stage, length of follow-up, and choice of
end points differed across all studies of GST enzymes.
Other Pathways and Findings of Interest
Positive but unvalidated studies have suggested associ-
ations between matrix metalloproteinase (MMP) polymor-
phisms and OS,54,55 UGT1A1/ABCC2 polymorphisms in iri-
notecan-treated patients and OS/PFS,56,57 vitamin D receptor
polymorphisms and OS in early-stage squamous cell carci-
noma and all-stage NSCLC,58,59 MTHFR polymorphisms
with OS/PFS,60,61 and VEGF polymorphisms in patients not
treated with VEGF-targeting agents.62 Studies of L-myc poly-
morphisms were discordant,63,64 and associations with indi-
vidual CYP polymorphisms and variable outcomes were
seen.65–67 All await confirmatory studies.
DISCUSSION
In 90 publications, the impact of germline genetic
polymorphisms as predictive and/or prognostic markers in
lung cancer has been modest at best. Strong consistent evi-
dence, involving large-scale validation is lacking, partly be-
cause most of studies were hypothesis-generating. The poly-
morphisms shown in Table 1 had at least two studies with
statistically significant results in the same direction consistent
with the replicate study and warrant further study. Yet, many
of these (e.g., p53Arg72Pro) consisted of multiple negatively
associated studies, which are mostly underpowered, in the
presence of two or three significantly positive yet modest-
sized studies. Even in the most consistent data of EGFR
intron 1 (CA)n S/L and ERCC1 codon 118, differing outcome
measures (RR, OS) and underpowered negative studies are
present. This sobering fact highlights two main aspects that
warrant further discussion—the inconsistency in study de-
sign, methodology, and reporting of results across studies and
potential strategies for improving further research. In the case
of ERCC1 codon 118 (platinum therapy) and EGFR intron 1
(CA)n (EGFR tyrosine kinase inhibitor drugs) polymor-
phisms, differing results may be easily explained using phar-
macogenetic principles, because polymorphic associations
are expected to be different in treated versus untreated pa-
tients. There is also the possibility that inconsistent associa-
tions with SNPs may result from ethnic-related differences in
allele frequencies. In other cases, there were no obvious
explanations.
In general, there was lack of uniformity in reporting
key study characteristics involving methods, patient popula-
tion, and treatment across studies. ReMARK guidelines68
have been developed for cancer biomarker assessments but
were rarely followed. For instance, important clinical and
prognostic factors were often omitted (53% of the studies that
involved at least some advanced-stage patients did not report
performance status, and smoking history was absent in 36%).
The source of the population (community, hospital-based,








XRCC1 Arg399Gln 10 Gln PG In four of five studies with platinum-treated patients, the Gln allele was
protective for OS/RR. No OS association was seen in nonplatinum-
treated patients.
ERCC1 codon 118C/T 9 C PG In three Asian studies, the T allele had worse outcomes (OS, RR) in
patients treated with platinum (no difference in absence of platinum).
This effect may be race-specific as no associations were seen in four
Caucasian studies.
ERCC1 8092A 6 C PG In platinum-treated patients, the C allele was associated with worse OS in
two Caucasian studies. With predominant carboplatin-based therapy, the
C allele was associated with better outcome in a single Caucasian study.
EGFR intron 1 (CA)n S/L 7 S PG In four studies with gefitinib-treated patients, a trend to improved outcomes
was seen with shorter alleles, while the opposite association was seen in
non-gefitinib treated patients.
EGFR-G216T 3 G PG In gefitinib-treated patients, the G allele alone or in haploytpe combination
was associated with worse outcome (PFS, OS) in two Caucasian studies.
p53Arg72Pro 6 Pro Prognostic Associations with worse outcomes in three Asian studies. A single
Caucasian study reported a shorter survival with the Pro/Pro genotype,
no association was seen in a second study nor in a third with a
predominant Caucasian population.
MDM2 T309G 2 G Prognostic The G allele was associated with worse OS in two studies despite different
ethnic populations and different disease stages.
GSTM1-null/present 6 Null Prognostic In two studies involving all histologies and all stages, the null genotype
was associated with worse OS.
S, short; L, long; PG, pharmacogenetic; OS, overall survival; RR, response rate; PFS, progression-free survival.
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clinical trial sample) and the study design (retrospective,
case-control, etc.) were in many cases not stated clearly.
Moreover, most studies did not report race or ethnicity data.
We relied on assumptions on ethnicity based on study loca-
tions and institutes. In particular, few of the 30 European
studies reported race distribution of the population. As men-
tioned above, this is particularly worrisome as ethnic-related
differences in allele frequencies may result in variable asso-
ciations with SNPs, highlighting the importance of detailed
reporting of ethnicity in all studies. The omission of key data
only minimally improved in recent years, further highlighting
this ongoing problem. Adaptation of ReMARK guidelines to
pharmacogenetic or polymorphism outcome analyses could
be developed to improve the quality of reported data.
While a meta-analysis or secondary pooled data anal-
ysis could better define the association between individual
polymorphisms and lung cancer outcome, the methodological
variation between studies and in particular different demo-
graphic, ethnic, stage, histologic, and treatment distributions
render such a meta-analysis unfeasible. Furthermore, neither
a meta-analysis nor a pooled analysis is appropriate as there
were so few studies suitable for combination once these
differences in race and treatment were accounted for. While
different end points are important to specific hypotheses,
future studies should use standardized definitions for mea-
sures of outcome and nontraditional end points and surrogate
measures avoided.
Three additional issues with the studies reviewed exist:
(1) predictive assessments of a polymorphism require inclu-
sion of both treated and untreated subjects drawn from the
same underlying pool of patients; thus, observational studies
rarely are able to evaluate the predictive nature of a genetic
biomarker and clinical trial analyses are required; (2) a
proportion of the studies have been underpowered to detect
significant associations between the polymorphism and the
relevant outcome; and (3) the analysis of large numbers of
polymorphisms raises the problem of multiple testing, which
further erodes statistical power.
With the establishment of validated molecular tech-
niques, clinical predictors of outcome can be enhanced by the
addition of single or panels of molecular and polymorphic
biomarkers. Yet, polymorphic prognosis research has been
hampered by an unrelenting focus on hypothesis generation,
and investment in large-scale validation studies is needed.
Furthermore, because tumor characteristics are likely to
trump many aspects of host genetics in survival analyses,
changing the focus and evaluating host predictors of toxicity,
where the effect is on the host rather than treatment response
or survival, should be of greater priority.
Future research should involve large-scale, prospective
clinical trials or carefully designed large-scale population-
based studies to collect comprehensive clinical data in a
systematic manner. This approach encourages uniformity and
rigor in design, minimizes potential study bias, captures
phenotype data prospectively, and facilitates interstudy com-
parisons. By comparing two or more treatment groups, this
approach can help determine whether the candidate polymor-
phisms are not only prognostic but also predictive of treat-
ment response.
Traditionally, a candidate gene approach is used to
select polymorphic biomarkers. Although this benefits from
being hypothesis-driven, there are limitations: (1) a candidate
gene approach that only considers a few genes or polymor-
phisms may miss important associations of polymorphisms
that were not chosen and (2) evidence for functionality of a
polymorphism is often contradictory. Recently, research has
focused on assessing haplotypes. SNPs within haplotype
blocks are in strong linkage disequilibrium; thus, having
genetic information on one SNP provides significant infor-
mation about others within the same haplotype block.69–71
The majority of the genetic variation across a gene can be
assessed using a much smaller number of SNPs, known as
“tagging” SNPs.72 Ma et al.37 used the whole gene-based
tag-SNP approach to determine the candidate polymorphisms
of EGFR that may predict outcome in advanced NSCLC
patients treated with gefitinib. Kim et al.73 used this approach
to identify associations of four tagging BRCA1 polymor-
phisms with outcome in NSCLC treated with platinum-based
chemotherapy. This technique may be less biased when
compared with a candidate gene/polymorphism approach
with the potential to reduce the cost and effort required to
undertake large-scale association studies.
Genes rarely act alone. Interactions between different
gene variants in a pathway or across different pathways may
occur, and a pathway approach to analysis offers a method-
ological advance. This method first involves the selection of
candidate genes that form a clearly defined biologic pathway
for the outcome of interest; then, based on the theory of
linkage disequilibrium, “tagging” polymorphisms are se-
lected to represent the majority of variation across the gene
and tested for association with the outcomes of interest.74 If
an association with polymorphisms is found, this is followed
by appropriate functional genomic evaluation. Wu et al.75
used a pathway approach to evaluate clinical outcomes in
advanced lung cancer patients treated with cisplatin in rela-
tion to genetic variations in drug action pathways and found
a group of six nucleotide excision pathway polymorphisms
that was progressively associated with OS. In contrast,
Matakidou et al.76 also used the pathway approach to identify
15 prognostic SNP markers in DNA repair genes with lung
cancer outcomes but did not find any SNP interactions with
platinum therapy in their observation dataset. Although
promising, these studies require replication.
Finally, genome-wide association studies (GWAS) rep-
resent a further advance. Using high-throughput genotyping
technologies, these studies assess genetic variability across
the genome to allow interrogation of the entire human ge-
nome and relate polymorphic variants to diseases.77 Identified
associations are then replicated in an independent population
sample. Large-scale biostatistical and bioinformatic resources
must underpin GWAS. This approach is not biased by prior
hypotheses regarding genetic associations with disease out-
come.78 However, the approach is limited by the need for
large sample sizes and by false-positive results that may
result from large numbers of statistical tests. In addition, lack
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of information on gene function, insensitivity to rare variants,
and possible biases due to population selection are important
limitations of GWAS.79 A combination of strategies is likely
needed, along with multiple validation/test sets (Figure 2).
Although data are lacking as yet in lung cancer, there are
recent examples of GWAS in the pharmacogenetic assess-
ment of toxicity or efficacy in the noncancer field.80,81 Fo-
cusing on idiosyncratic or clearly defined toxicity phenotypes
is the key to success in this field.
In summary, pharmacogenetic and genetic polymor-
phism analyses of outcomes are attractive as putative means
of improving outcome prediction and for individualizing
treatment in patients with lung cancer. To date, however,
results have been inconsistent. Table 1 outlines the few
polymorphisms that have the strongest data, yet each of these
polymorphisms still requires further validation. This list
should be considered a starting point only for future studies.
Methodological and statistical discrepancies may, in part,
account for the lack of replication of positive findings, but a
major reason is the lack of large-scale confirmatory studies.
To further enhance the chances of finding true associations,
other approaches including haplotype tagging, pathway, ge-
nome-wide association, and multiple validation approaches
should be considered. More importantly, a combination of the
approaches may identify true genetic determinants that will
facilitate a more accurate approach to disease outcome pre-
diction and ultimately facilitate genetically tailored treatment
strategies.
ACKNOWLEDGMENTS
Supported by Alan B. Brown Chair in Molecular
Genomics; Ontario Institute for Cancer Research Operating
Grants; Posluns Family Foundation; Cancer Care Ontario
Chair in Experimental Therapeutics and Population Studies;
and Division of Hematology/Oncology, Princess Margaret
Hospital/University Health Network, University of Toronto,
Ontario, Canada (to A.H.).
REFERENCES
1. Hopkins J, Cescon DW, Tse D, et al. Genetic polymorphisms and head
and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers
Prev 2008;17:490–499.
2. Bosken CH, Wei Q, Amos CI, et al. An analysis of DNA repair as a
determinant of survival in patients with non-small-cell lung cancer.
J Natl Cancer Inst 2002;94:1091–1099.
3. Shellard SA, Fichtinger-Schepman AM, Lazo JS, et al. Evidence of
differential cisplatin-DNA adduct formation, removal and tolerance of
DNA damage in three human lung carcinoma cell lines. Anticancer
Drugs 1993;4:491–500.
4. Giachino DF, Ghio P, Regazzoni S, et al. Prospective assessment of
XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymor-
phisms in lung cancer. Clin Cancer Res 2007;13:2876–2881.
5. Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymor-
phisms predict favorable clinical outcome in advanced non-small-cell
lung cancer. Clin Lung Cancer 2009;10:118–123.
6. de las Penas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in
DNA repair genes modulate survival in cisplatin/gemcitabine-treated
non-small-cell lung cancer patients. Ann Oncol 2006;17:668–675.
7. Sun X, Li F, Sun N, et al. Polymorphisms in XRCC1 and XPG and
response to platinum-based chemotherapy in advanced non-small cell
lung cancer patients. Lung Cancer 2009;65:230–236.
8. Sreeja L, Syamala VS, Syamala V, et al. Prognostic importance of DNA
repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln
in lung cancer patients from India. J Cancer Res Clin Oncol 2008;134:
645–652.
9. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic
polymorphisms are prognostic factors in advanced non-small-cell lung
cancer patients treated with platinum chemotherapy. J Clin Oncol
2004;22:2594–2601.
10. Petty WJ, Knight SN, Mosley L, et al. A pharmacogenomic study of
docetaxel and gemcitabine for the initial treatment of advanced non-
small cell lung cancer. J Thorac Oncol 2007;2:197–202.
11. Yoon SM, Hong YC, Park HJ, et al. The polymorphism and haplotypes
of XRCC1 and survival of non-small-cell lung cancer after radiotherapy.
Int J Radiat Oncol Biol Phys 2005;63:885–891.
12. Pillot GA, Read WL, Hennenfent KL, et al. A phase II study of irinotecan
and carboplatin in advanced non-small cell lung cancer with pharmacog-
enomic analysis: final report. J Thorac Oncol 2006;1:972–978.
13. Wang Z, Xu B, Lin D, et al. XRCC1 polymorphisms and severe toxicity
in lung cancer patients treated with cisplatin-based chemotherapy in
Chinese population. Lung Cancer 2008;62:99–104.
14. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum
based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331–344.
15. Britten RA, Liu D, Tessier A, et al. ERCC1 expression as a molecular
marker of cisplatin resistance in human cervical tumor cells. Int J
Cancer 2000;89:453–457.
16. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision
repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
Biochem Pharmacol 2000;60:1305–1313.
17. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression
correlates with prolonged survival after cisplatin plus gemcitabine che-
motherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286–
2291.
18. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels
complement thymidylate synthase mRNA levels in predicting response
and survival for gastric cancer patients receiving combination cisplatin
and fluorouracil chemotherapy. J Clin Oncol 1998;16:309–316.
19. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate
synthase mRNA levels predict survival for colorectal cancer patients
receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin
Oncol 2001;19:4298–4304.
20. Park SY, Hong YC, Kim JH, et al. Effect of ERCC1 polymorphisms and
the modification by smoking on the survival of non-small cell lung
cancer patients. Med Oncol 2006;23:489–498.
21. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms
of ERCC1 and XPD and survival in non-small-cell lung cancer patients
treated with cisplatin combination chemotherapy. Lung Cancer 2004;
44:311–316.
22. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response
in advanced non-small cell lung cancer. Lung Cancer 2007;56:281–288.
23. Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair
cross-complementation group 1 (ERCC1) single nucleotide polymor-
phisms on the prognosis of non-small cell lung cancer patients. Lung
Cancer 2010;67:101–107.
24. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and
grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer
Res 2005;11:1534–1538.
25. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1,
and XPD polymorphisms with response and survival in gemcitabine/
cisplatin-treated advanced non-small cell lung cancer patients. Clin
Cancer Res 2008;14:1797–1803.
FIGURE 2. Future combined approach of germline genetic
polymorphism studies in determining associations with can-
cer outcomes.
Horgan et al. Journal of Thoracic Oncology • Volume 6, Number 2, February 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer302
26. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-
complementation group 1 polymorphism predicts overall survival in
advanced non-small cell lung cancer patients treated with platinum-
based chemotherapy. Clin Cancer Res 2004;10:4939–4943.
27. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression,
signal pathway, and inhibitors in non-small cell lung cancer. Semin
Oncol 2002;29:38–44.
28. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor
of the epidermal growth factor receptor tyrosine kinase, in symptomatic
patients with non-small cell lung cancer: a randomized trial. JAMA
2003;290:2149–2158.
29. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the
epidermal growth factor receptor underlying responsiveness of non-
small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
30. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—
molecular and clinical predictors of outcome. N Engl J Med 2005;353:
133–144.
31. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor
receptor intron 1 polymorphism mediates response to epidermal growth
factor receptor inhibitors. Cancer Res 2004;64:9139–9143.
32. Nie Q, Wang Z, Zhang GC, et al. The epidermal growth factor receptor
intron1 (CA) n microsatellite polymorphism is a potential predictor of
treatment outcome in patients with advanced lung cancer treated with
Gefitinib. Eur J Pharmacol 2007;570:175–181.
33. Gregorc V, Hidalgo M, Spreafico A, et al. Germline polymorphisms in
EGFR and survival in patients with lung cancer receiving gefitinib. Clin
Pharmacol Ther 2008;83:477–484.
34. Ichihara S, Toyooka S, Fujiwara Y, et al. The impact of epidermal
growth factor receptor gene status on gefitinib-treated Japanese patients
with non-small-cell lung cancer. Int J Cancer 2007;120:1239–1247.
35. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor
receptor polymorphisms and clinical outcomes in non-small-cell lung
cancer patients treated with gefitinib. Pharmacogenomics J 2008;8:129–
138.
36. Han SW, Jeon YK, Lee KH, et al. Intron 1 CA dinucleotide repeat
polymorphism and mutations of epidermal growth factor receptor and
gefitinib responsiveness in non-small-cell lung cancer. Pharmacogenet
Genomics 2007;17:313–319.
37. Ma F, Sun T, Shi Y, et al. Polymorphisms of EGFR predict clinical
outcome in advanced non-small-cell lung cancer patients treated with
Gefitinib. Lung Cancer 2009;66:114–119.
38. Dubey S, Stephenson P, Levy DE, et al. EGFR dinucleotide repeat
polymorphism as a prognostic indicator in non-small cell lung cancer.
J Thorac Oncol 2006;1:406–412.
39. Cusatis G, Gregorc V, Li J, et al. Pharmacogenetics of ABCG2 and
adverse reactions to gefitinib. J Natl Cancer Inst 2006;98:1739–1742.
40. Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor
suppressor gene alterations and clinicopathological features in resected
lung cancers. Cancer Epidemiol Biomarkers Prev 1999;8:625–634.
41. Dumont P, Leu JI, Della Pietra AC III, et al. The codon 72 polymorphic
variants of p53 have markedly different apoptotic potential. Nat Genet
2003;33:357–365.
42. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53
modulates response to chemotherapy in vitro and in vivo. Oncogene
2004;23:3328–3337.
43. Sreeja L, Syamala V, Raveendran PB, et al. p53 Arg72Pro polymor-
phism predicts survival outcome in lung cancer patients in Indian
population. Cancer Invest 2008;26:41–46.
44. Boldrini L, Gisfredi S, Ursino S, et al. Prognostic impact of p53 Pro72
homozygous genotype in non-small cell lung cancer patients. Oncol Rep
2008;19:771–773.
45. Wang YC, Lee HS, Chen SK, et al. Prognostic significance of p53 codon
72 polymorphism in lung carcinomas. Eur J Cancer 1999;35:226–230.
46. Han JY, Lee GK, Jang DH, et al. Association of p53 codon 72
polymorphism and MDM2 SNP309 with clinical outcome of advanced
nonsmall cell lung cancer. Cancer 2008;113:799–807.
47. Matakidou A, El Galta R, Webb EL, et al. Lack of evidence that p53
Arg72Pro influences lung cancer prognosis: an analysis of survival in
619 female patients. Lung Cancer 2007;57:207–212.
48. Mechanic LE, Bowman ED, Welsh JA, et al. Common genetic variation
in TP53 is associated with lung cancer risk and prognosis in African
Americans and somatic mutations in lung tumors. Cancer Epidemiol
Biomarkers Prev 2007;16:214–222.
49. Boldrini L, Gisfredi S, Ursino S, et al. Effect of the p53 codon 72 and
intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prog-
nosis. Cancer Invest 2008;26:168–172.
50. Heist RS, Zhou W, Chirieac LR, et al. MDM2 polymorphism, survival,
and histology in early-stage non-small-cell lung cancer. J Clin Oncol
2007;25:2243–2247.
51. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the
MDM2 gene: from a molecular and cellular explanation to clinical
effect. Cancer Res 2005;65:5481–5484.
52. Sweeney C, Nazar-Stewart V, Stapleton PL, et al. Glutathione S-
transferase M1, T1, and P1 polymorphisms and survival among lung
cancer patients. Cancer Epidemiol Biomarkers Prev 2003;12:527–533.
53. Gonlugur U, Pinarbasi H, Gonlugur TE, et al. The association between
polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and
lung cancer outcome. Cancer Invest 2006;24:497–501.
54. Heist RS, Marshall AL, Liu G, et al. Matrix metalloproteinase polymor-
phisms and survival in stage I non-small cell lung cancer. Clin Cancer
Res 2006;12:5448–5453.
55. Jin G, Miao R, Hu Z, et al. Putative functional polymorphisms of MMP9
predict survival of NSCLC in a Chinese population. Int J Cancer
2009;124:2172–2178.
56. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A
polymorphisms predictive for pharmacokinetics and treatment outcome
in patients with non-small-cell lung cancer treated with irinotecan and
cisplatin. J Clin Oncol 2006;24:2237–2244.
57. Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and
ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical
outcome in patients with advanced non-small cell lung cancer. Cancer
2007;110:138–147.
58. Heist RS, Zhou W, Wang Z, et al. Circulating 25-hydroxyvitamin D,
VDR polymorphisms, and survival in advanced non-small-cell lung
cancer. J Clin Oncol 2008;26:5596–5602.
59. Zhou W, Heist RS, Liu G, et al. Polymorphisms of vitamin D receptor
and survival in early-stage non-small cell lung cancer patients. Cancer
Epidemiol Biomarkers Prev 2006;15:2239–2245.
60. Matakidou A, El Galta R, Rudd MF, et al. Prognostic significance of
folate metabolism polymorphisms for lung cancer. Br J Cancer 2007;
97:247–252.
61. Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and
pharmacogenetic study of pemetrexed compared with pemetrexed plus
carboplatin in pretreated patients with advanced non-small-cell lung
cancer. J Clin Oncol 2009;27:2038–2045.
62. Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in
early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856–862.
63. Ge H, Lam WK, Lee J, et al. Analysis of L-myc and GSTM1 genotypes
in Chinese non-small cell lung carcinoma patients. Lung Cancer 1996;
15:355–366.
64. Kawashima K, Nomura S, Hirai H, et al. Correlation of L-myc RFLP
with metastasis, prognosis and multiple cancer in lung-cancer patients.
Int J Cancer 1992;50:557–561.
65. Goto I, Yoneda S, Yamamoto M, et al. Prognostic significance of germ
line polymorphisms of the CYP1A1 and glutathione S-transferase genes
in patients with non-small cell lung cancer. Cancer Res 1996;56:3725–
3730.
66. Haque AK, Au W, Cajas-Salazar N, et al. CYP2E1 polymorphism,
cigarette smoking, p53 expression, and survival in non-small cell lung
cancer: a long term follow-up study. Appl Immunohistochem Mol Mor-
phol 2004;12:315–322.
67. Pan JH, Han JX, Wu JM, et al. CYP450 polymorphisms predict clinic
outcomes to vinorelbine-based chemotherapy in patients with non-small-
cell lung cancer. Acta Oncol 2007;46:361–366.
68. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommen-
dations for tumor MARKer prognostic studies (REMARK). Breast
Cancer Res Treat 2006;100:229–235.
69. Dawson E, Abecasis GR, Bumpstead S, et al. A first-generation linkage
disequilibrium map of human chromosome 22. Nature 2002;418:544–
548.
70. Daly MJ, Rioux JD, Schaffner SF, et al. High-resolution haplotype
structure in the human genome. Nat Genet 2001;29:229–232.
Journal of Thoracic Oncology • Volume 6, Number 2, February 2011 Germline Prognostic Markers of Lung Cancer
Copyright © 2011 by the International Association for the Study of Lung Cancer 303
71. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of
haplotype blocks in the human genome. Science 2002;296:2225–
2229.
72. Thompson D, Stram D, Goldgar D, et al. Haplotype tagging single
nucleotide polymorphisms and association studies. Hum Hered 2003;56:
48–55.
73. Kim HT, Lee JE, Shin ES, et al. Effect of BRCA1 haplotype on survival
of non-small-cell lung cancer patients treated with platinum-based che-
motherapy. J Clin Oncol 2008;26:5972–5979.
74. Suh Y, Vijg J. SNP discovery in associating genetic variation with
human disease phenotypes. Mutat Res 2005;573:41–53.
75. Wu X, Lu C, Ye Y, et al. Germline genetic variations in drug action
pathways predict clinical outcomes in advanced lung cancer treated with
platinum-based chemotherapy. Pharmacogenet Genomics 2008;18:955–
965.
76. Matakidou A, el Galta R, Webb EL, et al. Genetic variation in the DNA
repair genes is predictive of outcome in lung cancer. Hum Mol Genet
2007;16:2333–2340.
77. Christensen K, Murray JC. What genome-wide association studies can
do for medicine. N Engl J Med 2007;356:1094–1097.
78. Hirschhorn JN, Daly MJ. Genome-wide association studies for common
diseases and complex traits. Nat Rev Genet 2005;6:95–108.
79. Pearson TA, Manolio TA. How to interpret a genome-wide association
study. JAMA 2008;299:1335–1344.
80. Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cyto-
chrome P450 2C19 genotype with the antiplatelet effect and clinical
efficacy of clopidogrel therapy. JAMA 2009;302:849–857.
81. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of
response to clopidogrel and cardiovascular events. N Engl J Med
2009;360:363–375.
Horgan et al. Journal of Thoracic Oncology • Volume 6, Number 2, February 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer304
